«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2022 03

Page:

442-450

Research Field:

Publishing date:

Info

Title:

Clinical significance and prognostic value of systemic inflammation response index in breast cancer patients

Author(s):

ZHU Mengliu¹; CHEN Li¹; 2; KONG Xiangyi¹; WANG Xiangyu¹; LI Xingrui²; FANG Yi¹; WANG Jing¹

1.Department of Breast Surgical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;2.Department of Thyroid and Breast Surgery,Tongji Hospital,Tongji Medical College of Huazhong University of Science and Technology,Hubei Wuhan 430030,China.

Keywords:

breast cancer; neoadjuvant chemotherapy; systemic inflammation response index(SIRI); prognosis; disease-free survival(DFS); overall survival(OS)

PACS:

R737.9

DOI:

10.3969/j.issn.1672-4992.2022.03.014

Abstract:

Objective:To explore the clinical and prognostic value of the systemic inflammatory response index(SIRI) in breast cancer patients.Methods:The study included 477 breast cancer patients who underwent neoadjuvant chemotherapy and 308 breast cancer patients who did not receive neoadjuvant chemotherapy in our center between January 1998 and December 2016.Optimal SIRI threshold values were determined using the receiver operating characteristic curve(ROC).Patients were then reclassified as SIRI¡Ý0.80 group(high SIRI group) and SIRI£¼0.80 group(low SIRI group).The outcomes were analyzed by statistical methods.Results:Univariate and multivariate analyses demonstrated that SIRI independently predicted survival in breast cancer.The disease-free survival(DFS) and overall survival(OS) in patients with low SIRI scores were significantly longer in contrast to those with high SIRI scores(41.50 vs 37.63 months,and 64.57 vs 58.42 months).Further subgroup analyses revealed that low SIRI score patients who also had either early breast cancer,advanced breast cancer,or different molecular subtypes also possessed longer mean survival time of DFS and OS in contrast to those with high SIRI score(¦Ö2=2.379,P=0.123,and ¦Ö2=5.153,P=0.023,¦Ö2=11.080,P=0.000 9 and ¦Ö2=15.900,P< 0.000 1,¦Ö2=16.020,P<0.000 1 and ¦Ö2=22.050,P<0.000 1,respectively).Conclusion:SIRI serves as an easily accessible,replicable,and minimally invasive prognostic tool in breast cancer patients.Lower SIRI scores were predictive of a longer DFS and OS after surgery in breast cancer patients.SIRI may serve as a marker to guide clinical management and prognostication of breast cancer.

References:

[1]DAN,TAN J,HUANG J,et al.The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients£ÛJ£Ý.Breast Cancer,2020,27(5): 982-988.
[2]BRAY F,FERLAY J.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries(vol 68,pg 394,2018)£ÛJ£Ý.CA:A Cancer Journal for Clinicians,2020,70(4):313.
[3]CHEN W,ZHENG R,ZHANG S,et al.Cancer incidence and mortality in China in 2013:An analysis based.on urbanization level£ÛJ£Ý.Chinese Journal of Cancer Research,2017,29(1):1-10.
[4]CRUSZ SM,BALKWILL FR.Inflammation and cancer:advances and new agents£ÛJ£Ý.Nature Reviews Clinical.Oncology,2015,12(10):584-596.
[5]YOKOTANI T,IKEDA N,HIRAO T,et al.Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis£ÛJ£Ý.Surgery Today,2020,51(4):1-10.
[6]KOEHNE CH,RN DUBOIS.Cancer-related inflammation£ÛJ£Ý.Nature,2008,454(7203):436-444.
[7]DRUKKER K,EDWARDS A,DOYLE C,et al.Breast MRI radiomics for the pretreatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients£ÛJ£Ý.Journal of Medical Imaging,2019,6(3):034502.
[8]G¦BBORCSERNI,EWA CHMIELK,BALINT CSERNI,et al.The new TNM-based staging of breast cancer£ÛJ£Ý.Virchows Archiv An International,Journal of Pathology,2018,472(5): p.697-703.
[9]WEIGELT B,REIS-FILHO JS.Histological and molecular types of breast cancer: is there a unifying taxonomy£ÛJ£Ý.Nature Reviews Clinical Oncology,2009,6(12):718-730.
[10]HE Q,LI JY,REN QL.Efficacy of neoadjuvant single or dual anti-HER-2 therapy combined with chemotherapy in patients with HER-2-positive breast cancer: A single-center retrospective study£ÛJ£Ý.Asian Pacific Journal of Cancer Prevention,2021,22(5):1467-1475.
[11]THERASSE P.New guideline to evaluate the response to treatment in solid tumors£ÛJ£Ý.J Natl Cancer Inst,2000,92(3):205-216.
[12]AMAT S,F PENAULT-LLORCA,CURE H,et al.Scarff-bloom-richardson(SBR) grading:a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy£ÛJ£Ý.International Journal of Oncology,2002,20(4):791-796.
[13]KABA H,FUKUDA H,YAMAMOTO S,et al.Reliability at the national cancer institute-common toxicity criteria version 2.0£ÛJ£Ý.Gan To Kagaku Ryoho,2004,31(8):1187-1192.
[14]DIAKOS CI,CHARLES KA,MCMILLAN DC,et al.Cancer-related inflammation and treatment effectiveness£ÛJ£Ý.Lancet Oncology,2014,15(11):e493-e503.
[15]REBECCA,SIEGEL L,MPH,et al.Cancer statistics,2015£ÛJ£Ý.CA:A Cancer Journal for Clinicians,2020,70(1):7-30.
[16]TUFANO AM,TEPLINSKY E,LANDRY CA.Updates in neoadjuvant therapy for triple negative breast cancer£ÛJ£Ý.Clinical Breast Cancer,2021,21(1):1-9.
[17]COLOMER R,SAURA C,PEDRO S¦BNCHEZINOVIRA,et al.Neoadjuvant management of early breast cancer:A clinical and investigational position statement£ÛJ£Ý.Oncologist,2019,24(5):603-611.
[18]YU-JIA MA,DENG XL,HUI-QING LI.BRAFV600E mutation and its association with clinicopathological features of papillary thyroid microcarcinoma:A meta-analysis£ÛJ£Ý.Journal of Huazhong University of Science and Technology Medical Sciences,2015,35(004):591-599.
[19]ZHU Zhenfeng,XU Litao,ZHUANG Liping,et al.Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma£ÛJ£Ý.Oncotargets & Therapy,2018,11:6731-6740.
[20]LI B,WANG Y,DONG B,et al.Pretreatment systemic inflammation response index as an independent prognostic indicator for prostate cancer patients treated with maximal androgen blockade£ÛJ£Ý.Chinese Journal of Urology,2018,39(7):527-531.
[21]QI WX,XIANG Y,ZHAO S,et al.Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab£ÛJ£Ý.Cancer Immunology,Immunotherapy,2021,70(11):3199-3206.
[22]HUA X,LONG ZQ,HUANG X,et al.The preoperative systemic inflammation response index(SIRI) independently predicts survival in postmenopausal women with breast cancer£ÛJ£Ý.Current Problems in Cancer,2020,44(4):100560.
[23]GALDIERO MR,MARONE G,MANTOVANI A.Cancer inflammation and cytokines£ÛJ£Ý.Cold Spring Harbor,Perspectives in Biology,2018,10(8):a028662.
[24]CORBEAU I,JACOT W,GUIU S.Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast£ÛJ£Ý.Cancer Patients:A Systematic Review Cancers,2020,12(4):958.
[25]MORROW ES,ANTONIA R,JOANNE E.The role of gamma delta T lymphocytes in breast cancer:a review£ÛJ£Ý.Translational Research,2019,203:88-96.
[26]TAN DW,Y FU,SU Q,et al.Prognostic significance of neutrophil to lymphocyte ratio in oncologic outcomes of cholangiocarcinoma: A Meta-analysis£ÛJ£Ý.Scientific Reports,2016,6:33789.
[27]OLINGY CE,DINH HQ,HEDRICK CC.Monocyte heterogeneity and functions in cancer£ÛJ£Ý.Journal of Leukocyte Biology,2019,106(2):309-322.
[28]WEI L,XIE H,YAN P.Prognostic value of the systemic inflammation response index in human malignancy:A meta-analysis£ÛJ£Ý.Medicine,2020,99(50):e23486.
[29]ZHANG Y,LIU F,WANG Y.Evidence of the prognostic value of pretreatment systemic inflammation response.Index in cancer patients:A pooled analysis of 19 cohort studies£ÛJ£Ý.Disease Markers,2020,2020(5):1-10.
[30]WANG L,ZHOU Y,XIA S,et al.Prognostic value of the systemic inflammation response index(SIRI) before and after surgery in operable breast cancer patients£ÛJ£Ý.Cancer Biomarkers:Section A of Disease Markers,2020,28(4):1-11.
[31]YAMANO T,YAMAUCHI S,IGETA M,et al.Combination of preoperative tumour markers and lymphovascular invasion with TNM staging as a cost and labour efficient subtyping of colorectal cancer£ÛJ£Ý.Scientific Reports,2020,10(1):10238.
[32]SONG YJ,SHIN SH,CHO JS,et al.The role of lymphovascular invasion as a prognostic factor in patients with lymph node-positive operable invasive breast cancer£ÛJ£Ý.Journal of Breast Cancer,2011,14(3):198-203.

Memo

Memo:

National Natural Science Foundation of China(No.81872160£¬81372829£©£»¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð£¨±àºÅ£º81872160£¬81372829£©

Common functions

Last Update: 2021-12-31